Education
About Us
Working with TipRanks
Follow Us
Appili Therapeutics Inc Class A (APLIF)
OTHER OTC:APLIF
APLIF Stock Chart & Stats
$0.01
>-$0.01(-8.10%)
At close: 4:00 PM EST
$0.01
>-$0.01(-8.10%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.03
Previous CloseN/A
Volume100.00
Average Volume (3M)43.77K
Market Cap
$1.88M
Enterprise Value$14.82M
Total Cash (Recent Filing)$212.75K
Total Debt (Recent Filing)$12.46M
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Jul 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding128,366,120
10 Day Avg. Volume6,020
30 Day Avg. Volume43,769
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.39
Price to Sales (P/S)5.13
P/FCF Ratio-1.70
Enterprise Value/Market Cap7.89
Enterprise Value/Revenue71.81
Enterprise Value/Gross Profit74.23
Enterprise Value/Ebitda-9.32
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Infectious-disease PipelineAppili’s concentration on antifungal and antibacterial clinical candidates (ATI-2307, ATI-1501) represents a durable strategic focus in a high-barrier therapeutic niche. Specialized anti-infective programs can attract non-dilutive government funding, long-term partnerships, and regulatory priority pathways, supporting sustained development momentum and strategic optionality over multiple quarters.
Strong Reported Revenue Growth RateA ~72% reported revenue growth rate indicates improving top-line momentum tied to program activity or contract/grant recognition. While absolute revenue is small, the trend signals commercial/contract progress and strengthens the company's ability to justify continued investment, partner interest, and resource allocation across clinical milestones.
Improving Cash-flow TrendCash generation has materially improved versus earlier periods, with TTM operating and free cash flow near breakeven. This trend reflects better cost control or timing of funding and extends runway, reducing immediate refinancing urgency and providing a firmer short-to-medium term base for completing planned clinical milestones.
Bears Say
Stressed Balance SheetNegative shareholders’ equity and sizeable debt relative to a very small asset base create structural financial fragility. This limits flexibility to fund concurrent programs, increases refinancing and covenant risk, and elevates the likelihood of dilutive capital raises or onerous financing terms until clinical progress materially de-risks the pipeline.
Persistent Operating LossesSustained operating losses and a deeply negative net income profile mean the company cannot self-fund development. Continued negative margins drain resources, constrain investment in additional indications or larger trials, and make the company dependent on external capital or partner deal economics to advance programs long term.
Dependence On External Funding ModelAs a pre-commercial biotech, Appili relies on grants, collaborations, and equity financing rather than recurring product revenue. This structural dependence exposes the company to capital-market cyclicality and dilution risk, and ties program continuity to the timing and availability of non-dilutive support or partner deals until commercialization is achieved.
Appili Therapeutics Inc Class A News
APLIF FAQ
What was Appili Therapeutics Inc Class A’s price range in the past 12 months?
Appili Therapeutics Inc Class A lowest stock price was <$0.01 and its highest was $0.03 in the past 12 months.
What is Appili Therapeutics Inc Class A’s market cap?
Appili Therapeutics Inc Class A’s market cap is $1.88M.
When is Appili Therapeutics Inc Class A’s upcoming earnings report date?
Appili Therapeutics Inc Class A’s upcoming earnings report date is Jul 01, 2026 which is in 118 days.
How were Appili Therapeutics Inc Class A’s earnings last quarter?
Appili Therapeutics Inc Class A released its earnings results on Feb 12, 2026. The company reported -$0.005 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.005.
Is Appili Therapeutics Inc Class A overvalued?
According to Wall Street analysts Appili Therapeutics Inc Class A’s price is currently Overvalued.
Does Appili Therapeutics Inc Class A pay dividends?
Appili Therapeutics Inc Class A does not currently pay dividends.
What is Appili Therapeutics Inc Class A’s EPS estimate?
Appili Therapeutics Inc Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Appili Therapeutics Inc Class A have?
Appili Therapeutics Inc Class A has 128,366,120 shares outstanding.
What happened to Appili Therapeutics Inc Class A’s price movement after its last earnings report?
Appili Therapeutics Inc Class A reported an EPS of -$0.005 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Appili Therapeutics Inc Class A?
Currently, no hedge funds are holding shares in APLIF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Appili Therapeutics Inc Class A
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.